What really happens when you stop taking Ozempic

What did @raulthetrainer actually say?

The trainer shared a personal experiment: he stopped GLP-1 medication for a year to prove he could keep the weight off through exercise and diet alone. He gained 20 pounds. His takeaway was that GLP-1 drugs work, but stopping them brings back both the weight and what he calls "the noise" — the constant mental pull toward food. He argues that patients must learn calorie deficit habits while on the drug, otherwise stopping it leaves them with no tools to maintain their weight.

He frames GLP-1 medications similarly to blood pressure drugs: conditions that require ongoing treatment. His practical advice centers on protein intake, calorie distribution across meals, and planned snacking as skills to build during treatment.

Does the science back this up?

Pretty well, actually. The weight regain data on GLP-1 discontinuation is some of the clearest in obesity medicine right now.

The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who stopped semaglutide after 20 weeks regained roughly two-thirds of their lost weight within a year. Average regain was about 7 percentage points of body weight. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar patterns with tirzepatide: people who switched to placebo after an open-label phase regained substantial weight compared to those who continued treatment.

The "food noise" framing also has biological grounding. GLP-1 receptors in the hypothalamus modulate appetite signaling. When you remove the drug, that suppression lifts. Research by Batterham et al. has documented the neurological appetite dysregulation that underlies obesity, which does not resolve simply because someone loses weight. So yes, the hunger comes back. That is not a willpower failure. It is physiology.

What did they get wrong (or right)?

He got the big picture right. Weight regain after stopping GLP-1 medications is well-documented and not a character flaw. The blood pressure medication analogy is imperfect but not wrong — obesity is increasingly classified as a chronic condition requiring long-term management, a position supported by the American Association of Clinical Endocrinology.

Where his advice oversimplifies: the claim that learning calorie deficits "the right way" will prevent regain after stopping these drugs is not well-supported by clinical data. The STEP 4 trial participants received intensive behavioral counseling alongside semaglutide and still regained significantly. Behavioral interventions alone, post-discontinuation, have not been shown to reliably prevent regain at the population level.

His protein and calorie-distribution advice is reasonable general nutrition guidance, but presenting it as a reliable off-ramp from GLP-1 therapy oversells what lifestyle habits can do against restored physiological hunger drives. He is a trainer, not a clinician, and this distinction matters when someone is deciding whether to stop a prescribed medication.

What should you actually know?

GLP-1 receptor agonists like semaglutide and tirzepatide appear to function more like ongoing treatments for a chronic condition than short-term interventions. Stopping them typically restores appetite and, with it, weight. This is biology, not failure.

That said, the trainer's instinct to build sustainable habits during treatment is not wrong. Research does suggest that muscle mass preservation through resistance training and adequate protein intake can improve body composition outcomes. Cava et al. (2017, Nutrients) noted that higher protein diets help preserve lean mass during caloric restriction, which matters for long-term metabolic rate.

Anyone considering stopping a GLP-1 medication should have that conversation with a licensed prescriber, not a fitness creator on TikTok. Discontinuation decisions involve cardiovascular risk factors, metabolic markers, and individual health history that a trainer cannot assess. The decision to stop or continue is a clinical one.